BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 15004434)

  • 21. Effect of vasopeptidase inhibitor omapatrilat on cardiomyocyte apoptosis and ventricular remodeling in rat myocardial infarction.
    Bäcklund T; Palojoki E; Saraste A; Grönholm T; Eriksson A; Lakkisto P; Vuolteenaho O; Nieminen MS; Voipio-Pulkki LM; Laine M; Tikkanen I
    Cardiovasc Res; 2003 Mar; 57(3):727-37. PubMed ID: 12618234
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Omapatrilat increases renal endothelin in deoxycorticosterone acetate-salt hypertensive rats.
    Elmarakby AA; Morsing P; Pollock JS; Pollock DM
    Vascul Pharmacol; 2003 Dec; 40(5):253-9. PubMed ID: 15259792
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Renal hemodynamic and natriuretic effects of concomitant Angiotensin-converting enzyme and neutral endopeptidase inhibition in men.
    Regamey F; Maillard M; Nussberger J; Brunner HR; Burnier M
    Hypertension; 2002 Sep; 40(3):266-72. PubMed ID: 12215465
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of omapatrilat in low, normal, and high renin experimental hypertension.
    Trippodo NC; Robl JA; Asaad MM; Fox M; Panchal BC; Schaeffer TR
    Am J Hypertens; 1998 Mar; 11(3 Pt 1):363-72. PubMed ID: 9544878
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Attenuation of cardiovascular remodeling in DOCA-salt rats by the vasopeptidase inhibitor, omapatrilat.
    Loch D; Hoey A; Brown L
    Clin Exp Hypertens; 2006 Jul; 28(5):475-88. PubMed ID: 16820344
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antihypertensive and antihypertrophic effects of omapatrilat in SHR.
    Burrell LM; Droogh J; Man in't Veld O; Rockell MD; Farina NK; Johnston CI
    Am J Hypertens; 2000 Oct; 13(10):1110-6. PubMed ID: 11041166
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mechanism of vasopeptidase inhibitor-induced plasma extravasation: comparison of omapatrilat and the novel neutral endopeptidase 24.11/angiotensin-converting enzyme inhibitor GW796406.
    Sulpizio AC; Pullen MA; Edwards RM; Louttit JB; West R; Brooks DP
    J Pharmacol Exp Ther; 2005 Dec; 315(3):1306-13. PubMed ID: 16144980
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of neutral endopeptidase (neprilysin) inhibition on the response to other vasoactive peptides in small human resistance arteries: studies with thiorphan and omapatrilat.
    Dalzell JR; Seed A; Berry C; Whelan CJ; Petrie MC; Padmanabhan N; Clarke A; Biggerstaff F; Hillier C; McMurray JJ
    Cardiovasc Ther; 2014 Feb; 32(1):13-8. PubMed ID: 24138103
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vasopeptidase inhibition has beneficial cardiac effects in spontaneously diabetic Goto-Kakizaki rats.
    Grönholm T; Cheng ZJ; Palojoki E; Eriksson A; Bäcklund T; Vuolteenaho O; Finckenberg P; Laine M; Mervaala E; Tikkanen I
    Eur J Pharmacol; 2005 Sep; 519(3):267-76. PubMed ID: 16137672
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of a vasopeptidase inhibitor with neutral endopeptidase and angiotensin-converting enzyme inhibitors on bradykinin metabolism in the rat coronary bed.
    Dumoulin MJ; Adam A; Rouleau JL; Lamontagne D
    J Cardiovasc Pharmacol; 2001 Apr; 37(4):359-66. PubMed ID: 11300648
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chronic vasopeptidase inhibition restores endothelin-converting enzyme activity and normalizes endothelin levels in salt-induced hypertension.
    Quaschning T; d'Uscio LV; Shaw S; Viswambharan H; Ruschitzka FT; Lüscher TF
    Nephrol Dial Transplant; 2001 Jun; 16(6):1176-82. PubMed ID: 11390717
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of the vasopeptidase inhibitor omapatrilat on cardiac endogenous kinins in rats with acute myocardial infarction.
    Blais C; Lapointe N; Rouleau JL; Clément R; Gervais N; Geadah D; Adam A
    Peptides; 2001 Jun; 22(6):953-62. PubMed ID: 11390026
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Omapatrilat: penetration across the blood-brain barrier and effects on ischaemic stroke in rats.
    Schmedt Auf der Günne W; Zhao Y; Hedderich J; Gohlke P; Culman J
    Naunyn Schmiedebergs Arch Pharmacol; 2015 Sep; 388(9):939-51. PubMed ID: 25953200
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Regression of ventricular and vascular hypertrophy: are there differences between structurally different angiotensin-converting enzyme inhibitors?
    Raasch W; Bartels T; Schwartz C; Häuser W; Rütten H; Dominiak P
    J Hypertens; 2002 Dec; 20(12):2495-504. PubMed ID: 12473875
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Portal pressure responses and angiotensin peptide production in rat liver are determined by relative activity of ACE and ACE2.
    Herath CB; Lubel JS; Jia Z; Velkoska E; Casley D; Brown L; Tikellis C; Burrell LM; Angus PW
    Am J Physiol Gastrointest Liver Physiol; 2009 Jul; 297(1):G98-G106. PubMed ID: 19389807
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of omapatrilat on pharmacodynamic biomarkers of neutral endopeptidase and Angiotensin-converting enzyme activity in humans.
    Vesterqvist O; Reeves RA
    Curr Hypertens Rep; 2001 Dec; 3 Suppl 2():S22-7. PubMed ID: 11716802
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of neutral endopeptidase inhibition and combined angiotensin converting enzyme and neutral endopeptidase inhibition on angiotensin and bradykinin peptides in rats.
    Campbell DJ; Anastasopoulos F; Duncan AM; James GM; Kladis A; Briscoe TA
    J Pharmacol Exp Ther; 1998 Nov; 287(2):567-77. PubMed ID: 9808682
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vasopeptidase inhibition normalizes blood pressure and restores endothelial function in renovascular hypertension.
    Quaschning T; Hocher B; Ruhl S; Kraemer-Guth A; Tilgner J; Wanner C; Galle J
    Kidney Blood Press Res; 2006; 29(6):351-9. PubMed ID: 17139187
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vasopeptidase inhibition and Ang-(1-7) in the spontaneously hypertensive rat.
    Ferrario CM; Averill DB; Brosnihan KB; Chappell MC; Iskandar SS; Dean RH; Diz DI
    Kidney Int; 2002 Oct; 62(4):1349-57. PubMed ID: 12234305
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Investigation of bradykinin metabolism in human and rat plasma in the presence of the dual ACE/NEP inhibitors GW660511X and omapatrilat.
    Heudi O; Ramirez-Molina C; Marshall P; Amour A; Peace S; McKeown S; Abou-Shakra F
    J Pept Sci; 2002 Nov; 8(11):591-600. PubMed ID: 12487427
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.